Literature DB >> 10690857

Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone-releasing hormone analog: results of a prospective, randomized trial.

M V Mericq1, M Eggers, A Avila, G B Cutler, F Cassorla.   

Abstract

To study the effects of delaying puberty in GH-deficient (GHD) children, we studied 21 GHD (9 boys, 14 girls), treatment-naive, pubertal patients in a prospective, randomized trial. Their chronological age was 14.3 +/- 1.6 yr, and their bone age was 11.3 +/- 1.1 yr (mean +/- SD) at the beginning of the study. Four patients who developed hypogonadotropic hypogonadism were subsequently excluded from the study. Patients were randomly assigned to receive GH + LH-releasing hormone analog (LHRH-A) (n = 7), or GH alone (n = 10). GH and LHRH-A treatment started simultaneously in each patient. GH (Nutropin) was administered at a dose of 0.1 U/kg x day sc, until patients reached a bone age (BA) of 14 yr in girls and 16 yr in boys, and LHRH-A (Lupron depot) was administered at a dose of 300 microg/ kg every 28 days in during 3 yr. We defined GH deficiency as patients with a growth velocity less than 4 cm/yr, BA delay more than 1 yr in relationship to chronological age, GH response to two stimulation tests less than 7 microg/L, associated with low serum insulin-like growth factor I and insulin-like growth factor binding protein 3 levels. Statistical analysis was performed by ANOVA or Kruskall Wallis when variances were not homogeneous. We observed a significant decrease in the rate of BA maturation in the group treated with GH+LHRH-A (1.5 +/- 0.2 yr) compared with the group treated with GH alone (4.2 +/-0.5 yr) during the 3 years of LHRH-A therapy (P < 0.05). This delay in BA maturation produced a significant gain in final height in the group treated with GH+LHRH-A, which reached - 1.3 +/- 0.5 SD score compared with -2.7 +/- 0.3 SD score (P < 0.05) in the group treated with GH alone. These results indicate that delaying puberty with LHRH-A in GHD children during treatment with GH increases final height.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10690857     DOI: 10.1210/jcem.85.2.6343

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  Growth hormone therapy.

Authors:  Anurag Bajpai; P Sn Menon
Journal:  Indian J Pediatr       Date:  2005-02       Impact factor: 1.967

Review 2.  The use of somatropin (recombinant growth hormone) in children of short stature.

Authors:  Ameeta Mehta; Peter C Hindmarsh
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

3.  Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement.

Authors:  John D Mahan; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2006-05-30       Impact factor: 3.714

Review 4.  Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective.

Authors:  Paulo F Collett-Solberg; Geoffrey Ambler; Philippe F Backeljauw; Martin Bidlingmaier; Beverly M K Biller; Margaret C S Boguszewski; Pik To Cheung; Catherine Seut Yhoke Choong; Laurie E Cohen; Pinchas Cohen; Andrew Dauber; Cheri L Deal; Chunxiu Gong; Yukihiro Hasegawa; Andrew R Hoffman; Paul L Hofman; Reiko Horikawa; Alexander A L Jorge; Anders Juul; Peter Kamenický; Vaman Khadilkar; John J Kopchick; Berit Kriström; Maria de Lurdes A Lopes; Xiaoping Luo; Bradley S Miller; Madhusmita Misra; Irene Netchine; Sally Radovick; Michael B Ranke; Alan D Rogol; Ron G Rosenfeld; Paul Saenger; Jan M Wit; Joachim Woelfle
Journal:  Horm Res Paediatr       Date:  2019-09-12       Impact factor: 2.852

5.  Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years.

Authors:  Nelly Mauras; Lilliam Gonzalez de Pijem; Helen Y Hsiang; Paul Desrosiers; Robert Rapaport; I David Schwartz; Karen Oerter Klein; Ravinder J Singh; Anna Miyamoto; Kim Bishop
Journal:  J Clin Endocrinol Metab       Date:  2007-12-28       Impact factor: 5.958

Review 6.  Does the GH/IGF-1 axis contribute to skeletal sexual dimorphism? Evidence from mouse studies.

Authors:  Zhongbo Liu; Subburaman Mohan; Shoshana Yakar
Journal:  Growth Horm IGF Res       Date:  2015-12-31       Impact factor: 2.372

7.  Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature.

Authors:  Nelly Mauras; Judith L Ross; Priscila Gagliardi; Y Miles Yu; Jobayer Hossain; Joseph Permuy; Ligeia Damaso; Debbie Merinbaum; Ravinder J Singh; Ximena Gaete; Veronica Mericq
Journal:  J Clin Endocrinol Metab       Date:  2016-10-06       Impact factor: 5.958

8.  Combined Treatment with Gonadotropin-releasing Hormone Analog and Anabolic Steroid Hormone Increased Pubertal Height Gain and Adult Height in Boys with Early Puberty for Height.

Authors:  Toshiaki Tanaka; Yasuhiro Naiki; Reiko Horikawa
Journal:  Clin Pediatr Endocrinol       Date:  2012-03-24

Review 9.  Advances in pubertal growth and factors influencing it: Can we increase pubertal growth?

Authors:  Ashraf Soliman; Vincenzo De Sanctis; Rania Elalaily; Said Bedair
Journal:  Indian J Endocrinol Metab       Date:  2014-11

Review 10.  Aromatase inhibitors for short stature in male children and adolescents.

Authors:  Niamh McGrath; Michael J O'Grady
Journal:  Cochrane Database Syst Rev       Date:  2015-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.